Carter Clive R D, Keeble James R, Thorpe Robin
Division of Immunobiology, NIBSC, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
Biologicals. 2004 Mar;32(1):37-47. doi: 10.1016/j.biologicals.2003.12.002.
It has previously been reported that the biological activity of the human hematopoetic cytokine granulocyte colony stimulating factor (G-CSF) was reduced following incubation with human serum. The mechanism of action of serum has remained elusive although a number of possible mechanisms have been suggested including inactivation due to binding to the serum protein alpha(2)-macroglobulin (alpha(2)M) and degradation by serum proteases. The aim of this study was to clarify the conditions required by serum to reduce the biological activity of the cytokine and to define the mechanism involved. It has also been noted that G-CSF obtained from a CHO expression system (and therefore considered a glycosylated molecule) was resistant to serum inactivation unlike G-CSF obtained from an E. coli expression system (considered to be non-glycosylated). We used an enzymatic approach to remove the carbohydrate residues from glycosylated G-CSF and tested this material for its stability in serum. We additionally used a mutated G-CSF lacking glycosylation sites. We concluded that glycosylation was important in protecting against serum inactivation. We observed that serum reduced the biological activity of non-glycosylated G-CSF in a dose, and temperature dependent manner and deduced that the mechanism of action was dependent upon alpha(2)M bound serum protease enzymes.
此前有报道称,人血清与人类造血细胞因子粒细胞集落刺激因子(G-CSF)孵育后,其生物活性会降低。尽管有人提出了一些可能的机制,包括与血清蛋白α2-巨球蛋白(α2M)结合导致失活以及被血清蛋白酶降解,但血清的作用机制仍不清楚。本研究的目的是阐明血清降低细胞因子生物活性所需的条件,并确定其中涉及的机制。还注意到,与从大肠杆菌表达系统获得的G-CSF(被认为是非糖基化的)不同,从CHO表达系统获得的G-CSF(因此被认为是糖基化分子)对血清失活具有抗性。我们采用酶法去除糖基化G-CSF中的碳水化合物残基,并测试该物质在血清中的稳定性。我们还使用了缺乏糖基化位点的突变型G-CSF。我们得出结论,糖基化对于防止血清失活很重要。我们观察到,血清以剂量和温度依赖性方式降低非糖基化G-CSF的生物活性,并推断其作用机制取决于与α2M结合的血清蛋白酶。